Radiofrequency ablation of benign thyroid nodules : A prospective, multi-institutional North American experience
Copyright © 2023 Elsevier Inc. All rights reserved..
BACKGROUND: Radiofrequency ablation for benign thyroid nodules aims to achieve a volume reduction rate of ≥50%. However, factors that predict treatment success have not been defined in a large-scale study.
METHODS: A prospective cohort study of biopsy-proven benign thyroid nodules treated with radiofrequency ablation at 3 institutions was performed. Patient demographics, nodule sonographic features, procedural data, and nodule volume reduction were evaluated. Binary logistic regression analysis was performed to identify features associated with treatment response.
RESULTS: A total of 620 nodules were analyzed. The pooled median volume reduction rate at 12 months was 70.9% (interquartile range 52.9-86.6). At 1 year follow-up, 78.4% of nodules reached treatment success with a volume reduction rate ≥50%. The overall complication rate was 3.2% and included temporary voice changes (n = 14), vasovagal episodes (n = 5), nodule rupture (n = 3), and lightheadedness (n = 2). No permanent voice changes occurred. Four patients developed postprocedural hypothyroidism. Large baseline nodule volume (>20 mL) was associated with a lower rate of successful volume reduction (odds ratio 0.60 [0.37-0.976]). Large nodules achieved treatment success by 12-month follow-up at a rate of 64.5%, compared with 81.4% for small nodules and 87.2% for medium nodules.
CONCLUSION: To our knowledge, this is the largest North American cohort of patients with benign thyroid nodules treated with radiofrequency ablation. Overall, radiofrequency ablation was an effective treatment option with a low risk of procedural complications. Large volume nodules (>20 mL) may be associated with a lower rate of successful reduction with radiofrequency ablation treatment.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:175 |
|---|---|
| Enthalten in: |
Surgery - 175(2024), 1 vom: 11. Jan., Seite 139-145 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Russell, Jonathon O [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 16.12.2023 Date Revised 01.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.surg.2023.07.046 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364447974 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364447974 | ||
| 003 | DE-627 | ||
| 005 | 20240201232011.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.surg.2023.07.046 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1277.xml |
| 035 | |a (DE-627)NLM364447974 | ||
| 035 | |a (NLM)37953141 | ||
| 035 | |a (PII)S0039-6060(23)00725-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Russell, Jonathon O |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Radiofrequency ablation of benign thyroid nodules |b A prospective, multi-institutional North American experience |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.12.2023 | ||
| 500 | |a Date Revised 01.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Elsevier Inc. All rights reserved. | ||
| 520 | |a BACKGROUND: Radiofrequency ablation for benign thyroid nodules aims to achieve a volume reduction rate of ≥50%. However, factors that predict treatment success have not been defined in a large-scale study | ||
| 520 | |a METHODS: A prospective cohort study of biopsy-proven benign thyroid nodules treated with radiofrequency ablation at 3 institutions was performed. Patient demographics, nodule sonographic features, procedural data, and nodule volume reduction were evaluated. Binary logistic regression analysis was performed to identify features associated with treatment response | ||
| 520 | |a RESULTS: A total of 620 nodules were analyzed. The pooled median volume reduction rate at 12 months was 70.9% (interquartile range 52.9-86.6). At 1 year follow-up, 78.4% of nodules reached treatment success with a volume reduction rate ≥50%. The overall complication rate was 3.2% and included temporary voice changes (n = 14), vasovagal episodes (n = 5), nodule rupture (n = 3), and lightheadedness (n = 2). No permanent voice changes occurred. Four patients developed postprocedural hypothyroidism. Large baseline nodule volume (>20 mL) was associated with a lower rate of successful volume reduction (odds ratio 0.60 [0.37-0.976]). Large nodules achieved treatment success by 12-month follow-up at a rate of 64.5%, compared with 81.4% for small nodules and 87.2% for medium nodules | ||
| 520 | |a CONCLUSION: To our knowledge, this is the largest North American cohort of patients with benign thyroid nodules treated with radiofrequency ablation. Overall, radiofrequency ablation was an effective treatment option with a low risk of procedural complications. Large volume nodules (>20 mL) may be associated with a lower rate of successful reduction with radiofrequency ablation treatment | ||
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Desai, Dipan D |e verfasserin |4 aut | |
| 700 | 1 | |a Noel, Julia E |e verfasserin |4 aut | |
| 700 | 1 | |a Hussein, Mohammad |e verfasserin |4 aut | |
| 700 | 1 | |a Toraih, Eman |e verfasserin |4 aut | |
| 700 | 1 | |a Seo, Stefanie |e verfasserin |4 aut | |
| 700 | 1 | |a Wolfe, Samantha |e verfasserin |4 aut | |
| 700 | 1 | |a Omar, Mahmoud |e verfasserin |4 aut | |
| 700 | 1 | |a Issa, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Orloff, Lisa A |e verfasserin |4 aut | |
| 700 | 1 | |a Tufano, Ralph P |e verfasserin |4 aut | |
| 700 | 1 | |a Kandil, Emad |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Surgery |d 1945 |g 175(2024), 1 vom: 11. Jan., Seite 139-145 |w (DE-627)NLM000023590 |x 1532-7361 |7 nnns |
| 773 | 1 | 8 | |g volume:175 |g year:2024 |g number:1 |g day:11 |g month:01 |g pages:139-145 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.surg.2023.07.046 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 175 |j 2024 |e 1 |b 11 |c 01 |h 139-145 | ||